A Comparison of the Iron - Clearing Properties of 1 , 2 - Dimethyl - 3 - Hydroxypyrid - 4 - One , 1 , 2 - Diethyl - 3 - Hydroxypyrid - 4 - One 9 and Deferoxamine
نویسندگان
چکیده
A comparative study of the iron-clearing properties of subcutaneously (SC) administered deferoxamine (DFO) with those of orally administered 1,2-dimethyl-3-hydroxypyrid-4-one (CP20) and 1.2-diethyI-3-hydroxypyrid-4-one (CP94) is presented. The studies were performed in both a non-ironoverloaded, bile duct-cannulated rat model and an ironloaded Cebus monkey model. All three drugs performed well in the rodent, promoting the excretion of iron in both the urine and the bile, with total iron output efficiencies of 2.8%.
منابع مشابه
Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines.
The iron chelator, deferoxamine, has demonstrated cytotoxicity against neuroblastoma cells. In this study we examined the in vitro antineuroblastoma activity of several potentially less expensive oral chelating agents. On a mole for mole basis, 1-hydroxypyridine-2-thionine (omadine) had 100 times the cytotoxicity of deferoxamine. 1,2-Dimethyl-3-hydroxypyrid-4-one also caused demonstrable cell d...
متن کاملAbility of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
In view of the profound functional and structural abnormalities shown in our previous studies in cultured, iron-loaded rat heart cells, we have examined the ability of the orally effective iron chelators dimethyl-3-hydroxypyrid-4-one (DMHP or L1) and diethyl-3-hydroxy-pyrid-4-one (DEHP or CP94) and of deferoxamine (DF) to reverse the damage caused by iron loading to heart cell organelles. At a ...
متن کاملIron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Several life-threatening complications of the common disorder sickle cell disease require management with red blood cell transfusions and, hence, long-term iron-chelating therapy. The efficacy of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) has not previously been determined in patients with sickle cell disease. We compared the efficacy of L1 to that of standard-dose subcutaneo...
متن کاملIn vivo testing of oral iron chelators intended for clinical use.
The effectiveness of 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) in increasing iron excretion in iron-loaded patients improved the propsects for replacing desferrioxamine (DF) with an oral chelating drug.’,’ L1 belongs to a new group of iron chelators, the a-ketohydroxypyridines (KHP); which are cheap to p ~ e p a r e ~ . ~ and orally active. Recently, a detailed article by Porter et al.’ on in vivo...
متن کاملZinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
AIMS To determine the changes in serum zinc concentration and the extent of urinary zinc excretion in patients with iron overload receiving the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) or desferrioxamine (DFX), and to correlate these results with blood glucose concentration. METHODS Serum zinc and ferritin concentrations, urinary zinc and iron excretion were regularly assayed...
متن کامل